Developer docs
API playgroundTry for free, no card

Search company profiles

Processa Pharmaceuticals

Full company profile

uuid0003ul3

Namestring
Processa Pharmaceuticals
Legal namestring
Processa Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) is a clinical-stage biopharmaceutical company headquartered in Hanover, Maryland, founded in 2015 by David Young, Sian Bigora, Wendy Guy, and Patrick Lin — veterans of Questcor Pharmaceuticals and Promet Therapeutics. The company develops drug candidates for oncology and other high unmet medical need diseases using a "regulatory science" approach: acquiring de-risked, clinical-stage assets from third-party licensors and applying the leadership team's cumulative 30+ years of FDA experience to design efficient approval pathways. Processa's pipeline consists of four licensed candidates: NGC-Cap (PCS6422 combined with capecitabine) for metastatic breast and colorectal cancer, where Phase 2 interim data showed up to 10x reduction in toxic catabolites; PCS499 for ulcerative necrobiosis lipoidica and Phase 2/3 FSGS; PCS12852 for gastroparesis (subject to a binding term sheet granting Intact Therapeutics an exclusive licensing option); and PCS11T for oncology applications.

The underlying technology is pharmaceutical rather than computational: NGC-Cap is a combination therapy in which PCS6422 modulates capecitabine metabolism to increase exposure to active anti-cancer metabolites while reducing toxic byproducts (FBAL). Processa's competitive differentiation is positioned as regulatory and operational expertise rather than novel molecular discovery, with the team claiming involvement in 100+ FDA meetings and 30+ drug approvals across prior roles at Questcor, Scilex, Alimera, and ICON.

Processa is pre-revenue with no commercial products and generates $0 in current revenue. Its business model is asset-light and partnership-driven: the company funds clinical development through small sequential public equity offerings (approximately $19M raised across three offerings in January 2024, January 2025, and June 2025), advances candidates to value-inflection milestones, and intends to out-license programs either before or after pivotal studies to larger pharmaceutical companies for commercialization. End-patient customers (cancer, NL, gastroparesis, and FSGS patients) are not yet reached directly; commercial counterparties are limited to licensing partners, with Intact Therapeutics representing the only announced out-licensing relationship to date. Marketing is conducted through SEC filings, press releases, and participation in healthcare conferences including BIO International Convention 2025 and the J.P. Morgan Healthcare Conference.

Short descriptiontext

Processa Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company that licenses and develops drug candidates for oncology and rare diseases using regulatory science expertise, planning to out-license assets to larger partners before or after pivotal studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHanover, United States
HQ citystring
Hanover
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage pharmaceuticals, oncology drug development, next generation chemotherapy, rare disease therapeutics, FDA regulatory science
Industry3 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-stage biopharmaceutical drug development
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Licensing/Out-licensing
TypeLicensing Royalties
Description

As a development-stage pharmaceutical company, Processa plans to out-license its drug candidates either just before or after pivotal studies. The company develops drugs and then identifies partners for commercialization.

processapharmaceuticals.com
2Future Product Sales
TypeHardware Sales
Description

Pre-commercial stage company with no current revenue. Future revenue expected from pharmaceutical product sales upon FDA approval.

processapharmaceuticals.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company that acquires and develops de-risked drug candidates for oncology and rare diseases with high unmet medical needs. The company leverages 30+ years of regulatory science expertise to advance pipeline assets through FDA approval, with plans to out-license candidates either before or after pivotal studies to larger pharmaceutical partners for commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 NGC-Cap treatment showed up to 10x reduction in toxic FBAL catabolites while maintaining comparable safety to standard capecitabine monotherapy
+2 more records
Product overview1 text field

Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing Next Generation Chemotherapy (NGC) drugs and treatments for high unmet medical needs. The company's product portfolio includes NGC-Cap (a combination of PCS6422 and capecitabine for breast cancer), PCS499 for Ulcerative Necrobiosis Lipoidica and FSGS, PCS12852 for gastroparesis, and PCS11T for cancer treatment. Processa uses a regulatory science approach to de-risk drug development by acquiring clinical-stage assets and leveraging prior research to efficiently navigate FDA approval.

Product and service2 records
1NGC-Cap (PCS6422 + Capecitabine)
CategoryOncology drug candidate
Description

Next Generation Chemotherapy (NGC) combination therapy pairing Processa's proprietary PCS6422 with capecitabine, designed to make standard chemotherapy safer and more effective for patients with advanced or metastatic breast and colorectal cancer.

2PCS499
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeOthersAnnounced on2026-01-12
Description

Processa Pharmaceuticals attended the 44th Annual J.P. Morgan Healthcare Conference to engage potential partners and investors.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Processa signed a binding term sheet granting Intact Therapeutics an exclusive option to license the Phase 2 gastroparesis drug candidate (PCS12852).

3BIO International Convention 2025
Strategic tierMinorTypeOthersAnnounced on2025-06-13
Description

Processa participated in BIO International Convention 2025 to engage potential partners and investors.

processapharmaceuticals.com
Strategic tierCoreTypeTechnology or Integration
Description

Processa licensed PCS6422 from Elion Oncology, Inc. This is a core asset in their NGC (Next Generation Chemotherapy) pipeline for cancer treatment.

5CoNCERT Pharmaceuticals, Inc.
Strategic tierCoreTypeTechnology or Integration
Description

Processa licensed PCS499 from CoNCERT Pharmaceuticals, Inc. This drug candidate is being developed for ulcerative necrobiosis lipoidica and FSGS (Focal Segmental Glomerulosclerosis).

processapharmaceuticals.com
Strategic tierCoreTypeTechnology or Integration
Description

Processa licensed PCS12852 from Yuhan Corporation for gastroparesis and GI motility treatment development.

Strategic tierCoreTypeTechnology or Integration
Description

Processa licensed PCS11T from Aposense, LTD for oncology applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Heat Biologics
TypeDirect peer
Description

Clinical-stage immunotherapy company with multiple oncology programs and a small-cap public profile. Comparable in multi-asset oncology pipeline structure and clinical-stage development approach.

2Diffusion Pharmaceuticals
TypeDirect peer
Description

Small-cap, clinical-stage biotech developing novel oncology supportive-care and therapeutic candidates. Comparable in scale, oncology development focus, and reliance on partnership/capital markets.

TypeBroad incumbent
Description

Larger specialty oncology pharmaceutical company with both clinical and commercial assets. Referenced in Processa's CEO/CFO background; comparable as a broader specialty pharma competitor in similar oncology indications, though operating at significantly greater scale.

TypeDirect peer
Description

Clinical-stage oncology-focused biotech developing small-molecule therapies targeting DNA damage response pathways. Comparable in oncology pipeline focus, clinical-stage development model, and small-cap public status.

TypeDirect peer
Description

Clinical-stage biotech with multiple late-stage programs in rare diseases and cell therapy. Comparable in small-cap public profile, multi-program pipeline, and reliance on partnership/external funding to advance trials.

TypeDirect peer
Description

Small-cap, clinical-stage biopharmaceutical company developing multiple in-licensed/acquired candidates across CNS, immunology, and rare diseases. Closely comparable in scale, multi-asset pipeline structure, and out-licensing/partnership orientation.

TypeDirect peer
Description

Clinical-stage pharmaceutical company developing oncology drug candidates with small headcount and public small-cap profile. Directly comparable business model and oncology pipeline focus.

TypeDirect peer
Description

Small-cap specialty pharmaceutical company with a mix of clinical-stage and commercial assets. Comparable in sub-scale market cap, public listing structure, and pharma portfolio orientation.

9Celsion Corporation
TypeDirect peer
Description

Small-cap, clinical-stage oncology company with lead assets in late-stage trials. Comparable in oncology focus, sub-scale market cap, and clinical-milestone-driven valuation dynamics.

10CoNCERT Pharmaceuticals
TypeEmerging player
Description

Clinical-stage small-molecule developer that licensed PCS499 to Processa. Comparable in clinical-stage small-molecule development approach and therapeutic-area focus (dermatology/rare disease), and serves as both licensor and developmental parallel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Processa Pharmaceuticals

Clinical-stage biopharmaceutical drug developmentprocessapharmaceuticals.com

Processa Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company that licenses and develops drug candidates for oncology and rare diseases using regulatory science expertise, planning to out-license assets to larger partners before or after pivotal studies.

What Processa Pharmaceuticals does

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) is a clinical-stage biopharmaceutical company headquartered in Hanover, Maryland, founded in 2015 by David Young, Sian Bigora, Wendy Guy, and Patrick Lin — veterans of Questcor Pharmaceuticals and Promet Therapeutics. The company develops drug candidates for oncology and other high unmet medical need diseases using a "regulatory science" approach: acquiring de-risked, clinical-stage assets from third-party licensors and applying the leadership team's cumulative 30+ years of FDA experience to design efficient approval pathways. Processa's pipeline consists of four licensed candidates: NGC-Cap (PCS6422 combined with capecitabine) for metastatic breast and colorectal cancer, where Phase 2 interim data showed up to 10x reduction in toxic catabolites; PCS499 for ulcerative necrobiosis lipoidica and Phase 2/3 FSGS; PCS12852 for gastroparesis (subject to a binding term sheet granting Intact Therapeutics an exclusive licensing option); and PCS11T for oncology applications.

The underlying technology is pharmaceutical rather than computational: NGC-Cap is a combination therapy in which PCS6422 modulates capecitabine metabolism to increase exposure to active anti-cancer metabolites while reducing toxic byproducts (FBAL). Processa's competitive differentiation is positioned as regulatory and operational expertise rather than novel molecular discovery, with the team claiming involvement in 100+ FDA meetings and 30+ drug approvals across prior roles at Questcor, Scilex, Alimera, and ICON.

Processa is pre-revenue with no commercial products and generates $0 in current revenue. Its business model is asset-light and partnership-driven: the company funds clinical development through small sequential public equity offerings (approximately $19M raised across three offerings in January 2024, January 2025, and June 2025), advances candidates to value-inflection milestones, and intends to out-license programs either before or after pivotal studies to larger pharmaceutical companies for commercialization. End-patient customers (cancer, NL, gastroparesis, and FSGS patients) are not yet reached directly; commercial counterparties are limited to licensing partners, with Intact Therapeutics representing the only announced out-licensing relationship to date. Marketing is conducted through SEC filings, press releases, and participation in healthcare conferences including BIO International Convention 2025 and the J.P. Morgan Healthcare Conference.

Processa Pharmaceuticals firmographics

Firmographics
Name
Processa Pharmaceuticals
Legal name
Processa Pharmaceuticals, Inc.
Website
https://processapharmaceuticals.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Processa Pharmaceuticals is a pre-revenue, clinical-stage biopharmaceutical company that licenses and develops drug candidates for oncology and rare diseases using regulatory science expertise, planning to out-license assets to larger partners before or after pivotal studies.
Ownership category
akta.pro rank

Processa Pharmaceuticals industry classification

Industry
Product category
Clinical-stage biopharmaceutical drug development
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage pharmaceuticals
  • Oncology drug development
  • Next generation chemotherapy
  • Rare disease therapeutics
  • FDA regulatory science

Where Processa Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Hanover
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Processa Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Drug Licensing/Out-licensing: As a development-stage pharmaceutical company, Processa plans to out-license its drug candidates either just before or after pivotal studies. The company develops drugs and then identifies partners for commercialization.
  2. Future Product Sales: Pre-commercial stage company with no current revenue. Future revenue expected from pharmaceutical product sales upon FDA approval.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Processa Pharmaceuticals product offering

Product offering

Core offering

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company that acquires and develops de-risked drug candidates for oncology and rare diseases with high unmet medical needs. The company leverages 30+ years of regulatory science expertise to advance pipeline assets through FDA approval, with plans to out-license candidates either before or after pivotal studies to larger pharmaceutical partners for commercialization.

Product overview

Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing Next Generation Chemotherapy (NGC) drugs and treatments for high unmet medical needs. The company's product portfolio includes NGC-Cap (a combination of PCS6422 and capecitabine for breast cancer), PCS499 for Ulcerative Necrobiosis Lipoidica and FSGS, PCS12852 for gastroparesis, and PCS11T for cancer treatment. Processa uses a regulatory science approach to de-risk drug development by acquiring clinical-stage assets and leveraging prior research to efficiently navigate FDA approval.

Differentiator

Problem solved

Functional benefit

Products and services

  • NGC-Cap (PCS6422 + Capecitabine) Next Generation Chemotherapy (NGC) combination therapy pairing Processa's proprietary PCS6422 with capecitabine, designed to make standard chemotherapy safer and more effective for patients with advanced or metastatic breast and colorectal cancer.
  • PCS499

Quantifiable outcome

  • Phase 2 NGC-Cap treatment showed up to 10x reduction in toxic FBAL catabolites while maintaining comparable safety to standard capecitabine monotherapy
  • +2 more outcomes

Companies that use Processa Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles2 records

Processa Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Processa Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor, strategic and core.

  • J.P. Morgan Healthcare ConferenceminorOthers · 12 January 2026Processa Pharmaceuticals attended the 44th Annual J.P. Morgan Healthcare Conference to engage potential partners and investors.
  • Intact TherapeuticsstrategicStrategic or Co-development Partner · 17 June 2025Processa signed a binding term sheet granting Intact Therapeutics an exclusive option to license the Phase 2 gastroparesis drug candidate (PCS12852).
  • BIO International Convention 2025minorOthers · 13 June 2025Processa participated in BIO International Convention 2025 to engage potential partners and investors.
  • Elion Oncology, Inc.coreTechnology or IntegrationProcessa licensed PCS6422 from Elion Oncology, Inc. This is a core asset in their NGC (Next Generation Chemotherapy) pipeline for cancer treatment.
  • CoNCERT Pharmaceuticals, Inc.coreTechnology or IntegrationProcessa licensed PCS499 from CoNCERT Pharmaceuticals, Inc. This drug candidate is being developed for ulcerative necrobiosis lipoidica and FSGS (Focal Segmental Glomerulosclerosis).
  • Yuhan CorporationcoreTechnology or IntegrationProcessa licensed PCS12852 from Yuhan Corporation for gastroparesis and GI motility treatment development.
  • Aposense, LTDcoreTechnology or IntegrationProcessa licensed PCS11T from Aposense, LTD for oncology applications.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Processa Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Heat Biologics: Clinical-stage immunotherapy company with multiple oncology programs and a small-cap public profile. Comparable in multi-asset oncology pipeline structure and clinical-stage development approach.
  • Diffusion Pharmaceuticals: Small-cap, clinical-stage biotech developing novel oncology supportive-care and therapeutic candidates. Comparable in scale, oncology development focus, and reliance on partnership/capital markets.
  • Aprea Therapeutics: Clinical-stage oncology-focused biotech developing small-molecule therapies targeting DNA damage response pathways. Comparable in oncology pipeline focus, clinical-stage development model, and small-cap public status.
  • Capricor Therapeutics: Clinical-stage biotech with multiple late-stage programs in rare diseases and cell therapy. Comparable in small-cap public profile, multi-program pipeline, and reliance on partnership/external funding to advance trials.
  • Tonix Pharmaceuticals: Small-cap, clinical-stage biopharmaceutical company developing multiple in-licensed/acquired candidates across CNS, immunology, and rare diseases. Closely comparable in scale, multi-asset pipeline structure, and out-licensing/partnership orientation.
  • Moleculin Biotech: Clinical-stage pharmaceutical company developing oncology drug candidates with small headcount and public small-cap profile. Directly comparable business model and oncology pipeline focus.
  • Aytu BioPharma: Small-cap specialty pharmaceutical company with a mix of clinical-stage and commercial assets. Comparable in sub-scale market cap, public listing structure, and pharma portfolio orientation.
  • Celsion Corporation: Small-cap, clinical-stage oncology company with lead assets in late-stage trials. Comparable in oncology focus, sub-scale market cap, and clinical-milestone-driven valuation dynamics.

Broad incumbents

  • Spectrum Pharmaceuticals: Larger specialty oncology pharmaceutical company with both clinical and commercial assets. Referenced in Processa's CEO/CFO background; comparable as a broader specialty pharma competitor in similar oncology indications, though operating at significantly greater scale.

Emerging players

  • CoNCERT Pharmaceuticals: Clinical-stage small-molecule developer that licensed PCS499 to Processa. Comparable in clinical-stage small-molecule development approach and therapeutic-area focus (dermatology/rare disease), and serves as both licensor and developmental parallel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Processa Pharmaceuticals social profiles

Digital presence

Processa Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Processa Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

Processa Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Processa Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Processa Pharmaceuticals

What does Processa Pharmaceuticals do?

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company that acquires and develops de-risked drug candidates for oncology and rare diseases with high unmet medical needs. The company leverages 30+ years of regulatory science expertise to advance pipeline assets through FDA approval, with plans to out-license candidates either before or after pivotal studies to larger pharmaceutical partners for commercialization.

Is Processa Pharmaceuticals a public or private company?

Processa Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Processa Pharmaceuticals founded?

Processa Pharmaceuticals was founded in 2015. It employs 11 to 50 people.

Where is Processa Pharmaceuticals based?

Processa Pharmaceuticals is headquartered in Hanover, United States, in the North America region.

How does Processa Pharmaceuticals make money?

Two revenue lines are on record. Drug Licensing/Out-licensing is the primary driver. The others are future Product Sales.

Who are Processa Pharmaceuticals's main competitors?

Direct peers on record are Heat Biologics, Diffusion Pharmaceuticals, Aprea Therapeutics, Capricor Therapeutics, Tonix Pharmaceuticals, Moleculin Biotech, Aytu BioPharma and Celsion Corporation. Spectrum Pharmaceuticals is listed as a broad incumbent. CoNCERT Pharmaceuticals is listed as an emerging player.

Does Processa Pharmaceuticals have an API?

No public API is recorded for Processa Pharmaceuticals.

What industry is Processa Pharmaceuticals in?

Processa Pharmaceuticals's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaProcessa Pharmaceuticals, Inc. (PCSA) Presents at UBS Global Biopharma Conference 2026 TranscriptProcessa Pharmaceuticals CEO Sheila Gujrathi introduced the company's BTK inhibitor program at the UBS Global Biopharma Conference 2026, highlighting its potential for autoimmune and neurological indications. The program originated at Gossamer Bio and builds on her prior work in immunology at Genentech, BMS, and Receptos.Business & FinancialProcessa Pharmaceuticals To Participate In Upcoming Investor ConferencesProcessa Pharmaceuticals' executive chair will speak at two investor conferences on November 16 and December 2. The company acquired Vidya Therapeutics in July 2026 via a reverse merger and $200 million private placement. Its lead program is VT-7208, a BTK inhibitor for food allergy and other immune diseases.Stock TitanProcessa Pharmaceuticals appoints four executivesProcessa Pharmaceuticals appointed four executives to support its growth, including Gregory J. Flesher as COO and Craig Coburn as head of research. The appointments follow the July 2026 acquisition of Vidya Therapeutics and a concurrent private placement of approximately $200 million. The company is advancing its lead program VT-7208 across multiple immune-mediated diseases.GlobeNewswireProcessa Pharmaceuticals Announces Key Leadership AppointmentsProcessa Pharmaceuticals announced key leadership appointments, including Gregory J. Flesher as COO and Craig Coburn as head of research. The appointments follow the company's July 2026 acquisition of Vidya Therapeutics and a $200 million private placement. The team will support advancing VT-7208 across multiple immune-mediated diseases.TradingViewProcessa Pharmaceuticals Advances VT-7208, Expands Pipeline and Names Executive ChairProcessa Pharmaceuticals received FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria and appointed Sheila Gujrathi as Executive Chair. The company plans Phase 2 studies in food allergy and relapsing multiple sclerosis, and expects cash resources to fund operations into the second half of 2029.Investing.comProcessa gets FDA clearance for Phase 2 urticaria studyProcessa Pharmaceuticals received FDA clearance for a Phase 2 study of VT-7208 in chronic spontaneous urticaria. The multicenter, randomized, double-blind, placebo-controlled study will enroll about 120 adults and evaluate the drug over 12 weeks. The company plans to advance VT-7208 across three Phase 2 programs.San Diego Business JournalBiotech Revives Abandoned Drug, Emerges from Stealth, Lands $200MVidya Therapeutics was acquired by Processa Pharmaceuticals in a stock-for-stock deal, with Processa securing roughly $200 million in private placement proceeds. The funding will support clinical studies of VT-7208, a BTK inhibitor, in food allergies, chronic spontaneous urticaria, and relapsing multiple sclerosis.Stock TitanProcessa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisitionProcessa Pharmaceuticals closed a $200 million private placement of Series A Preferred Stock and acquired Vidya Therapeutics to advance its lead drug candidate, VT-7208. The transaction significantly alters the company's capital structure, with post-deal holders owning approximately 99% of common stock on an as-converted basis if preferred shares are converted. This funding aims to support operations through late 2029 following the termination of previous programs.Investing.comProcessa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting By Investing.comProcessa Pharmaceuticals shareholders approved an amendment to the company's 2019 Omnibus Incentive Plan at its annual meeting held on July 30, increasing the available shares for issuance by 200,000. The meeting also saw the re-election of all six directors and the ratification of Cherry Bekaert, LLP as the independent auditor for the fiscal year ending December 31, 2026. Additionally, shareholders passed an advisory vote on executive compensation.Investing.comProcessa Pharmaceuticals shareholders approve incentive plan amendment and board elections By Investing.comProcessa Pharmaceuticals shareholders approved an amendment to the 2019 Omnibus Incentive Plan, increasing available shares by 200,000, and elected six directors at the company's annual meeting on July 30. The vote also ratified Cherry Bekaert, LLP as the independent auditor and approved executive compensation. These governance updates are routine corporate actions required for ongoing operations.